• TBTA: What the Available Evidence Establishes

  2026-10-19

  The available APExBIO listing identifies TBTA under SKU C3001, but the provided product information does not state its expanded chemical identity, molecular formula, mechanism, measurement principle, or performance data. No identity-matched research paper is available, so mechanistic and application claims cannot be established from the cited material.

• 3 sgRNA EGFP Product: Evidence and Scope

  2026-10-18

  The APExBIO listing for SKU R2997 identifies a product described as three sgRNAs targeting EGFP for HELA cells, with 3 µmol stated for each guide. That description supports only a limited identity and intended-target interpretation. It does not provide guide sequences, Cas nuclease information, formulation, quality data, or evidence of editing performance. No identity-matched research study or outcome data are available, so the product should not be treated as independently validated for EGFP disruption, fluorescence loss, specificity, or cellular effects.

• ApexPrep Miniprep Kit: Evidence and Mechanism

  2026-10-17

  The ApexPrep DNA Plasmid Miniprep Kit is described by APExBIO as an alkaline-lysis, membrane-based system for isolating plasmid DNA from bacterial cultures. Its stated capacity, purity, copy-number range, and downstream applications are vendor claims rather than findings from an identity-matched research study, so interpretation should remain limited to the documented product scope.

• Amikacin Disulfate: Evidence and Scope

  2026-10-16

  APExBIO describes Amikacin disulfate as a semisynthetic aminoglycoside antibiotic whose documented antibacterial mechanism involves 16S rRNA within the bacterial 30S ribosomal subunit. Because no identity-matched research paper is available here, the mechanism and material properties should be treated as supplier-documented claims rather than independently validated findings.

• ECL Western Blotting Substrate: Evidence and Scope

  2026-10-16

  APExBIO’s ECL Western Blotting Substrate (SKU K2187) is described as a luminol-based, nonradioactive horseradish peroxidase detection reagent for chemiluminescent immunoblot imaging. The product description supports a conceptual HRP-to-light measurement pathway, but no identity-matched research study or comparative performance dataset is available to verify sensitivity, background, signal preservation, or equivalence to other ECL substrates.

• MagBeads PCR Purification Kit: Evidence Boundaries

  2026-10-15

  The APExBIO product entry identifies K1625 as a MagBeads PCR Purification Kit, but the available information does not document its bead chemistry, selectivity, recovery, contaminant removal, performance statistics, or use in a matched research study. A defensible interpretation is therefore limited to product identity and a broad sample-preparation role, not validated performance or experimentally established mechanism.

• AG-490: Mechanism and Evidence Boundaries

  2026-10-15

  AG-490, also known as Tyrphostin B42, is described by APExBIO as a multi-target tyrosine kinase inhibitor affecting JAK2, EGFR, and ErbB2, with reported cellular effects involving JAK-STAT, STAT3, STAT5, and MAPK-associated signaling. Because no identity-matched research paper is available here, the quantitative claims should be treated as supplier-reported evidence whose assay context, comparators, uncertainty, and independent reproducibility are not established.

• Aconitase Assay Kit: Scope and Evidence

  2026-10-14

  The APExBIO Aconitase Activity Colorimetric Assay Kit (SKU K2226) is described as a colorimetric format for estimating aconitase activity through citrate-to-isocitrate conversion and downstream color generation. Its documented mechanism supports interpretation as a biochemical activity readout, but the supplied information does not establish independent performance, oxidative-stress specificity, mitochondrial localization, or clinical meaning.

• RIPK3 Degradation, Necroptosis and NAE Signaling

  2026-10-14

  Liu et al. identify an orthopoxviral strategy that targets RIPK3 for proteasome-dependent degradation, linking viral immune evasion to necroptosis, inflammation and disease severity in mouse models. MLN4924 HCl salt is conceptually relevant because its supplier describes it as a NEDD8-activating enzyme inhibitor, but the supplied study does not establish that this compound was used or that NAE inhibition accounts for the reported viral phenotypes.

• Baicalin and Adult Visual Plasticity in Mice

  2026-10-13

  A 2026 NeuroImage study reports that Baicalin reactivated ocular dominance plasticity and improved visual function in an adult mouse model of amblyopia. The findings implicate reduced cortical GABAergic inhibition, but remain preclinical and do not establish efficacy, safety, or mechanism in humans.

• MCL-1 and Breast Cancer: What the Study Shows

  2026-10-13

  A 2021 Cell Death & Differentiation study examined whether MCL-1 supports breast cancer mainly through its canonical anti-apoptotic role or through non-apoptotic functions. Its findings link tumour dependence on MCL-1 to BAX/BAK-mediated mitochondrial apoptosis, while also identifying important model and translation limits.

• EBV, HDAC Inhibition, and NPC Plasticity

  2026-10-12

  A 2021 study examined how the EBV protein LMP1 promotes dedifferentiation in nasopharyngeal carcinoma and whether HDAC inhibition can restore a more differentiated cellular state. Its findings support a preclinical mechanism involving STAT5A, HDAC1/2, and CEBPA, but they do not establish clinical efficacy or implicate MMAE.

• Prochlorperazine: Evidence Boundaries

  2026-10-12

  The supplied evidence identifies Prochlorperazine as a dopamine D2 receptor antagonist with established antiemetic use, while the cited infectious-disease publication concerns icatibant rather than Prochlorperazine. Its discussion of hantavirus and COVID-19 therefore provides context about vascular-permeability pathways, not evidence that Prochlorperazine is an antiviral or a treatment for those infections.

• Caspase 3/7, Autophagy, and DNA Damage Response

  2026-10-10

  A 2025 PLOS Biology study shows that CASP3 and CASP7 support cytoprotective autophagy and DNA damage signaling during non-lethal stress in human breast cancer cells. The findings identify non-canonical CASP7 processing and a context-dependent vulnerability associated with BRCA1 loss, while also defining important limits for translating cell-model results into therapeutic claims.

• SFI’s Anti-Glioma Mechanism via SRC/PI3K/AKT

  2026-10-09

  The 2024 Journal of Ethnopharmacology study combines network pharmacology with cellular and animal evidence to investigate how Shenqi Fuzheng injection affects glioma proliferation and migration. Its central contribution is a testable association between SFI activity and SRC/PI3K/AKT pathway regulation, although the evidence remains preclinical and does not establish direct target causality or clinical efficacy.

555 records 1/37 page Next 12345 下5页 Last page